Browse by author
Lookup NU author(s): Emeritus Professor Philip Home
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND).
© 2017 The Authors. Aim: To explore if efficacy and safety findings for insulin glargine 300. U/mL (Gla-300) versus insulin glargine 100. U/mL (Gla-100), observed over 6 months in insulin-naïve people with type 2 diabetes, are maintained after 12 months. Methods: EDITION 3 was a phase 3a, randomized, multicentre, open-label, parallel-group, treat-to-target study of once-daily Gla-300 versus Gla-100 (target fasting self-monitored plasma glucose, 4.4-5.6. mmol/L [80-100. mg/dL]). Participants completing the initial 6-month treatment phase continued their previously allocated basal insulin. Results: Of 878 participants randomized, 337/439 (77%) and 314/439 (72%) assigned to Gla-300 and Gla-100, respectively, completed 12 months of treatment. Improved glycaemic control was sustained until 12 months in both treatment groups, with similar reductions in HbA1c from baseline to month 12 (difference: -0.08 [95% confidence interval (CI): -0.23 to 0.07] % or -0.9 [-2.5 to 0.8] mmol/mol). Relative risk of experiencing≥1 confirmed (≤3.9mmol/L [≤70mg/dL]) or severe hypoglycaemic event with Gla-300 versus Gla-100 was 0.86 (95% CI: 0.69 to 1.07) at night and 0.92 (0.82 to 1.03) at any time of day. For events with a glycaemic threshold of<3.0mmol/L (<54mg/dL) these numbers were 0.76 (0.49 to 1.19) and 0.66 (0.50 to 0.88). A similar pattern was seen for documented symptomatic events. No between-group differences in adverse events were identified. Conclusion: Over 12 months, Gla-300 treatment was as effective as Gla-100 in reducing HbA1c in insulin-naïve people with type 2 diabetes, with lower overall risk of hypoglycaemia at the<3.0mmol/L threshold.
Author(s): Bolli GB, Riddle MC, Bergenstal RM, Wardecki M, Goyeau H, Home PD
Publication type: Article
Publication status: Published
Journal: Diabetes and Metabolism
Year: 2017
Volume: 43
Issue: 4
Pages: 351-358
Print publication date: 01/09/2017
Online publication date: 13/06/2017
Acceptance date: 28/04/2017
Date deposited: 04/07/2017
ISSN (print): 1262-3636
ISSN (electronic): 1878-1780
Publisher: Elsevier Masson SAS
URL: https://doi.org/10.1016/j.diabet.2017.04.007
DOI: 10.1016/j.diabet.2017.04.007
Altmetrics provided by Altmetric
